search
Back to results

The POMELO (Prevention Of MusclE Loss in Osteoarthritis) Trial (POMELO)

Primary Purpose

Osteoarthritis, Knee, Obesity

Status
Active
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Intervention
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • body mass index (BMI) ≥35 kg/m2
  • unilateral or bilateral knee osteoarthritis (KL grade ≥2 and clinical symptoms)
  • able to provide written, informed consent in English
  • able to attend assessment appointments in Edmonton, Alberta
  • have reliable and unlimited access to internet and a laptop, computer or tablet at home for access to videoconferencing sessions
  • have space at home to complete exercises with equipment provided, or able to attend in-person exercise sessions

Exclusion Criteria:

  • any medical conditions where participation in resistance exercise or nutrition adjustments are contraindicated
  • neurological disorders (i.e. multiple sclerosis)
  • post-traumatic OA with a fracture that impacts joint (secondary to injury or accident)
  • rheumatoid arthritis
  • prior bariatric surgery
  • prior knee or hip replacement surgery
  • recently (within 3 months) taken anabolic steroids or other muscle building compounds

Sites / Locations

  • University of Alberta

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Usual Care

Arm Description

The intervention group will receive initial nutrition and exercise consultations with a Registered Dietitian (RD) and Clinical Exercise Physiologist (CEP) to personalize the study protocol and recommendations to their needs. The intervention period (3 months) includes: a) whole-body resistance training exercise sessions completed three-times per week (at-home with loaned equipment and/or in-person at the research gym); b) biweekly nutrition education provided through video conferencing; and c) biweekly OA self-management support provided through video conferencing. After the 3 month intervention, participants will receive bimonthly phone calls from a study staff member to encourage continued behavior changes during the 6 month maintenance phase.

The control group will follow standard care procedures, which includes their usual activities. The control group will receive bimonthly contact during the study period through phone calls with a study staff member to encourage retention. However no recommendations or advice on nutrition, exercise or self-management will be provided.

Outcomes

Primary Outcome Measures

Per-protocol adherence (feasibility)
per-protocol adherence to the intervention >= 60%
Adverse events
rates of adverse events in the intervention and control arms
Study completion rates (feasibility)
study completion rates >= 80%
Acceptability of Intervention Measure (AIM) score
AIM scores compared between the intervention and control groups
Qualitative data on participants perceptions of acceptability
qualitative data from open-ended survey and interview questions under each domain of the Theoretical Framework of Acceptability

Secondary Outcome Measures

muscle mass
appendicular lean mass assessed by DXA
physical function (chair stands)
number of chair stands in 30 seconds
physical function (6MWT distance)
6MWT distance

Full Information

First Posted
August 4, 2021
Last Updated
September 5, 2023
Sponsor
University of Alberta
Collaborators
The Arthritis Society, Canada
search

1. Study Identification

Unique Protocol Identification Number
NCT05026385
Brief Title
The POMELO (Prevention Of MusclE Loss in Osteoarthritis) Trial
Acronym
POMELO
Official Title
Targeted Knee Osteoarthritis Care for Adults With a BMI ≥35 kg/m2: the Prevention Of MusclE Loss in Osteoarthritis (P.O.M.E.L.O.) Feasibility and Pilot Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 20, 2021 (Actual)
Primary Completion Date
July 21, 2023 (Actual)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
Collaborators
The Arthritis Society, Canada

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Treatment options for individuals who have advanced knee osteoarthritis (OA) and a body mass index (BMI) ≥35 kg/m2 are limited, and this patient population may be neglected in current clinical care pathways for OA management. These individuals are considered to be at high risk for complications with total knee arthroplasty (TKA), and as a result may not be eligible for this procedure unless they lose significant weight. However, there is limited evidence for endorsing weight loss as beneficial prior to TKA. Further, unsupervised weight loss could put patients at risk for muscle loss and development of sarcopenic obesity, a health condition that negatively impacts mobility and mortality. This suggests that weight loss might not be the primary treatment goal for this patient population. Integrated non-surgical treatment approaches are needed that can target the specific needs of this knee OA patient group. This study will examine the feasibility and acceptability of a personalized, multicomponent intervention, and its effects on body composition and physical function compared to usual care.
Detailed Description
The primary objectives of the POMELO study are to determine if a multicomponent behavioural intervention that includes personalized nutrition recommendations, progressive resistance training exercise, and chronic disease self-management support is feasible and acceptable for individuals living with advanced knee OA and a BMI ≥35 kg/m2. The secondary objectives are to assess potential effects of the intervention on muscle mass and physical function compared to usual care. The intervention is delivered over three months, followed by six months of ongoing maintenance support. Assessments are completed at baseline, interim (after the 3 month intervention phase), and at study end (after the 6 month maintenance phase) [for a total study period of 10 months]. This project will inform and influence the future development and implementation of more personalized knee OA treatment approaches for adults with a BMI ≥35 kg/m2 and reduce health disparities in access to effective care. Findings will also contribute to improved health outcomes for this vulnerable patient population, and enhanced delivery of health services by offering an alternative treatment pathway targeted to patient needs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee, Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
The intervention group will receive initial nutrition and exercise consultations with a Registered Dietitian (RD) and Clinical Exercise Physiologist (CEP) to personalize the study protocol and recommendations to their needs. The intervention period (3 months) includes: a) whole-body resistance training exercise sessions completed three-times per week (at-home with loaned equipment and/or in-person at the research gym); b) biweekly nutrition education provided through video conferencing; and c) biweekly OA self-management support provided through video conferencing. After the 3 month intervention, participants will receive bimonthly phone calls from a study staff member to encourage continued behavior changes during the 6 month maintenance phase.
Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
The control group will follow standard care procedures, which includes their usual activities. The control group will receive bimonthly contact during the study period through phone calls with a study staff member to encourage retention. However no recommendations or advice on nutrition, exercise or self-management will be provided.
Intervention Type
Behavioral
Intervention Name(s)
Intervention
Intervention Description
Targeted nutrition advice, progressive resistance training exercise, and self-management support
Primary Outcome Measure Information:
Title
Per-protocol adherence (feasibility)
Description
per-protocol adherence to the intervention >= 60%
Time Frame
at interim (3 months)
Title
Adverse events
Description
rates of adverse events in the intervention and control arms
Time Frame
at interim (3 months)
Title
Study completion rates (feasibility)
Description
study completion rates >= 80%
Time Frame
at study completion (10 months)
Title
Acceptability of Intervention Measure (AIM) score
Description
AIM scores compared between the intervention and control groups
Time Frame
at interim (3 months) and study completion (10 months)
Title
Qualitative data on participants perceptions of acceptability
Description
qualitative data from open-ended survey and interview questions under each domain of the Theoretical Framework of Acceptability
Time Frame
at interim (3 months) and study completion (10 months)
Secondary Outcome Measure Information:
Title
muscle mass
Description
appendicular lean mass assessed by DXA
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
physical function (chair stands)
Description
number of chair stands in 30 seconds
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
physical function (6MWT distance)
Description
6MWT distance
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Other Pre-specified Outcome Measures:
Title
muscle quality
Description
change in ultrasound-measured thigh muscle volume and echogenicity
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
fat mass
Description
change in fat mass assessed by DXA
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
patient-reported health-related quality of life
Description
change in quality of life assessed by EQ-5D
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
patient-reported arthritis-related pain and function
Description
change in arthritis-related pain and function assessed by WOMAC
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
self-efficacy for managing chronic disease
Description
change in self-efficacy scores assessed by PROMIS
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
lipid panel
Description
change in blood assessed lipid panel (i.e. total cholesterol, LDL, HDL and triglycerides)
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
c-reactive protein
Description
change in blood assessed c-reactive protein
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
insulin
Description
change in blood assessed insulin
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
albumin
Description
change in blood assessed albumin
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
liver enzymes
Description
change in blood assessed liver enzymes (ALT and GGT)
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
glucose
Description
change in blood assessed glucose
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
thyroid stimulating hormone
Description
change in blood assessed thyroid stimulating hormone
Time Frame
change from baseline to interim (3 months) and study completion (10 months)
Title
resting energy expenditure
Description
change in resting energy expenditure using indirect calorimetry
Time Frame
change from baseline to interim (3 months) and study completion (10 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: body mass index (BMI) ≥35 kg/m2 unilateral or bilateral knee osteoarthritis (KL grade ≥2 and clinical symptoms) able to provide written, informed consent in English able to attend assessment appointments in Edmonton, Alberta have reliable and unlimited access to internet and a laptop, computer or tablet at home for access to videoconferencing sessions have space at home to complete exercises with equipment provided, or able to attend in-person exercise sessions Exclusion Criteria: any medical conditions where participation in resistance exercise or nutrition adjustments are contraindicated neurological disorders (i.e. multiple sclerosis) post-traumatic OA with a fracture that impacts joint (secondary to injury or accident) rheumatoid arthritis prior bariatric surgery prior knee or hip replacement surgery recently (within 3 months) taken anabolic steroids or other muscle building compounds
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carla Prado, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mary Forhan, PhD
Organizational Affiliation
University of Toronto
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kristine Godziuk, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2P5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The POMELO (Prevention Of MusclE Loss in Osteoarthritis) Trial

We'll reach out to this number within 24 hrs